|
Sections |
70.14.020 | State agencies to identify alternative health care providers. |
70.14.030 | Health care utilization review procedures. |
70.14.040 | Review of prospective rate setting methods. |
70.14.050 | Drug purchasing cost controls—Establishment of evidence-based prescription drug program. |
70.14.060 | Prescription drug purchasing consortium—Participation—Exceptions—Rules. |
70.14.065 | Generic prescription drug partnership agreements. |
70.14.070 | Prescription drug consortium account. |
70.14.080 | Definitions. |
70.14.090 | Health technology clinical committee. |
70.14.100 | Health technology selection and assessment. |
70.14.110 | Health technology clinical committee determinations. |
70.14.120 | Agency compliance with committee determination—Coverage and reimbursement determinations for nonreviewed health technologies—Appeals. |
70.14.130 | Health technology clinical committee—Public notice. |
70.14.140 | Applicability to health care services purchased from health carriers. |
70.14.150 | Data-sharing agreements—Report. |
70.14.155 | Streamlined health care administration—Agency participation. |
70.14.160 | Total cost of insulin work group—Appointment—Duties—Reporting. |
70.14.165 | Total cost of insulin work group—Authority implementation. |
70.14.170 | Opioid overdose reversal medications—Bulk purchasing and distribution—Rules—Report—Recommendation to legislature. |
70.14.175 | Opioid overdose reversal medication account. |